To the full analysis
Buyback calculator for Ironwood Pharmaceuticals
Ironwood Pharmaceuticals stock: key metrics
IRWDIronwood Pharmaceuticals had an operating margin of 40.1% and a return on invested capital (ROIC) of 36% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 0.0% | −1,261.0% | −1,184.1% |
| 2007 | 100.0% | −550.6% | −504.1% |
| 2008 | 100.0% | −251.7% | −242.5% |
| 2009 | 100.0% | −201.6% | −197.2% |
| 2010 | 100.0% | −138.6% | −120.8% |
| 2011 | 100.0% | −100.4% | −98.5% |
| 2012 | 99.4% | −48.4% | −48.3% |
| 2013 | 68.5% | −1,101.4% | −1,192.3% |
| 2014 | 66.5% | −221.6% | −248.1% |
| 2015 | 100.0% | −68.3% | −95.4% |
| 2016 | 99.3% | −18.9% | −29.8% |
| 2017 | 93.5% | −25.9% | −39.2% |
| 2018 | 90.6% | −68.9% | −81.5% |
| 2019 | 68.4% | 28.0% | no data |
| 2020 | 99.2% | 36.7% | 27.3% |
| 2021 | 83.0% | 56.1% | 127.7% |
| 2022 | 99.7% | 61.0% | 42.6% |
| 2023 | 98.6% | −213.5% | −226.4% |
| 2024 | 97.9% | 26.5% | 0.3% |
| 2025 | 100.0% | 40.1% | 8.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 0.0% | no data | 0.0% |
| 2007 | 28.5% | −42.5% | −38.8% |
| 2008 | 22.9% | −42.2% | −38.3% |
| 2009 | 23.6% | −54.8% | −43.8% |
| 2010 | −33.2% | −27.9% | −17.6% |
| 2011 | −59.0% | −27.4% | −31.0% |
| 2012 | −50.4% | −36.1% | −31.6% |
| 2013 | −100.0% | −96.4% | −97.8% |
| 2014 | −100.0% | −51.1% | −56.9% |
| 2015 | −100.0% | −18.9% | −23.0% |
| 2016 | −100.0% | −47.8% | −11.5% |
| 2017 | −100.0% | −37.9% | −19.3% |
| 2018 | 143.8% | −47.2% | −85.0% |
| 2019 | no data | 117.0% | no data |
| 2020 | 169.5% | 89.1% | 19.0% |
| 2021 | 87.2% | 75.7% | 46.9% |
| 2022 | 26.8% | 39.7% | 15.9% |
| 2023 | 200.0% | no data | −100.0% |
| 2024 | −0.3% | 19.1% | 0.3% |
| 2025 | −9.2% | 36.0% | 6.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 12 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.